Background: Chronic Myeloid Leukaemia (CML) is a myeloproliferative neoplasm (MPN) of abnormal marrow stem cell with BCR-ABL1 fusion gene as a pathognomonic feature. In resource-poor countries, clinical and laboratory parameters were invaluable tools used in the diagnosis. However, the advent of GeneXpert technology was a paradigm shift in the detection of the fusion gene. Aim of the study: To highlight the clinical usefulness of geneXpert in the evaluation of clinical and laboratory features of newly diagnosed patients. Patients and Methods: A cross-sectional descriptive study was conducted at University of Nigeria Teaching Hospital (UNTH) Enugu. Sixty-five BCR-ABL 1 positive consenting patients were evaluated using demographic, clinical and laboratory data. Data was analyzed using GraphPad Prism software version 9 with probability <0.05 as statistically significant. Results: A total of 65 patients with mean age 45.22 + 15.44 years were studied. Age group 39 – 49 were mostly affected 20 (30.8%) with Enugu State having the highest disease burden 20 (30.8%). Abdominal swelling was the most common presenting feature 57 (87.7%) while splenomegaly was the most common finding on imaging 60 (92.3%). Mean WBC and BCR-ABL1 were 207.37 + 87.57 x 109/L and 41.02 + 24.53% (IS) respectively (r = -180, P = 0.015). Majority of the cases were in chronic phase 56 (86.2%). Risk assessment of cases on presentation using Sokal and Hasford scores were statistically significant (t = 20.23, P < 0.0001), [CI = 1429 to 1739]. Conclusion: There was improved diagnostic yield of cases of CML using the molecular diagnostic technique.